APELOA(000739)2024-03-07 16:00Financial Performance - The company's operating revenue for 2023 reached ¥11,474,162,365.59, representing an increase of 8.81% compared to the previous year[46]. - Net profit attributable to shareholders was ¥1,055,340,740.79, reflecting a growth of 6.69% year-over-year[46]. - The net profit after deducting non-recurring gains and losses was ¥1,026,437,851.58, which is a significant increase of 22.73% from the previous year[46]. - Basic and diluted earnings per share increased to ¥0.9025, up 7.12% from the previous year[46]. - Total assets at the end of 2023 were ¥12,767,664,072.34, marking a 6.21% increase from the end of 2022[46]. - Net assets attributable to shareholders increased by 12.90% to ¥6,222,728,875.43 compared to the end of 2022[46]. - The company achieved total revenue of ¥11,474,162,365.59, representing an 8.81% increase year-over-year[103]. - The pharmaceutical main business generated revenue of ¥11,440,239,653.78, with a year-over-year growth of 8.89%[103]. - The innovative drug R&D and production services segment saw a revenue increase of 27.10%, reaching ¥2,004,981,793.08[103]. - The gross profit margin for the pharmaceutical main business improved to 25.60%, up by 1.71% compared to the previous year[103]. Dividend Distribution - The company plans to distribute a cash dividend of 3.16 yuan per 10 shares to all shareholders, based on a total of 1,169,323,576 shares[9]. Business Operations - The company reported a significant change in its main business from retail to pharmaceutical chemicals since December 2001[26]. - The company has undergone a change in its registered address, which was updated in April 2019[41]. - The company has confirmed that there are no significant discrepancies in financial indicators compared to previously disclosed quarterly and semi-annual reports[29]. - The company has engaged He Xin Accounting Firm for auditing services during the reporting period[45]. - The company emphasizes that the annual report contains forward-looking statements and does not constitute a substantive commitment to investors[33]. - The company has stated that all board members attended the meeting to review the annual report, ensuring its accuracy and completeness[8]. - The company has acknowledged potential risks in future operations and has outlined corresponding countermeasures[14]. - The company’s stock is listed on the Shenzhen Stock Exchange under the code 000739[41]. Research and Development - The company invested RMB 624.87 million in R&D during the reporting period, representing a 17.25% increase and accounting for 5.45% of total revenue[77]. - The company has submitted 363 patent applications and held 139 valid patents by the end of the reporting period[59]. - The company has registered 9 API products and 2 formulation products during the reporting period, with 5 formulation products submitted for domestic registration[78]. - The company has developed new technology platforms such as PROTAC and ADC, which are currently under construction and partially operational[77]. - The company has established new CDMO R&D centers in Hangzhou, Shanghai, and Boston, with over 500 R&D personnel[121]. - R&D personnel increased to 1,205 in 2023, a growth of 17.45% from 1,026 in 2022[1]. - The number of R&D personnel with master's degrees rose by 41.82% to 312 in 2023, compared to 220 in 2022[1]. - The number of R&D personnel aged under 30 increased by 28.44% to 840 in 2023, compared to 654 in 2022[1]. Production and Capacity - The company has launched a new production line for cephalosporin powder injection with an annual capacity of 100 million bottles, which commenced production in April[81]. - The company aims to achieve a production line for solid formulations by March 2024[81]. - The company has implemented 17 automation projects to enhance operational efficiency during the reporting period[82]. - The company has established 11 wastewater treatment systems with a designed capacity of 5.4 million tons[84]. - Production volume of formulations rose by 25.69% to 110,738,310 units[125]. - API projects totaled 82, a 49% increase year-on-year, with 18 entering commercialization[120]. Market Presence and Client Development - The company expanded its international market presence, with products exported to over 70 countries and regions[114]. - The company has established BD offices in key global markets including Boston, Frankfurt, Tokyo, and Mumbai[114]. - The CDMO business has signed confidentiality agreements with 414 domestic and international innovative pharmaceutical companies, with 55% of clients from abroad[98]. - The company added 25 new clients in the raw material pharmaceutical business, indicating good progress in new customer development[94]. Environmental and Compliance - The company has built a comprehensive environmental management system in compliance with ISO standards, improving its EHS capabilities[84]. - The company has enhanced its operational efficiency, with all pharmaceutical production and distribution subsidiaries certified by NMPA and multiple facilities passing FDA and EU EDQM inspections[90]. Governance and Management - The company’s governance structure includes a board of directors and an audit committee responsible for internal and external audit supervision[180]. - The company’s management structure consists of three business units: API, CDMO, and FDF, aimed at enhancing operational efficiency[180]. - The annual shareholders' meeting had a participation rate of 61.94% on April 18, 2023[182]. - The company is focused on continuous improvement in its business operations and product strategies through a flat organizational structure[180]. - The board members attended a total of 6 board meetings, with an average attendance of 3 in person[199]. - Independent directors receive an annual allowance of 100,000 yuan each, as approved by the shareholders' meeting[196].